MRK Merck and Co Inc

By Colin Kellaher

AstraZeneca PLC and Merck & Co. on Wednesday said the European Commission approved their cancer drug Lynparza in a form of pancreatic cancer.

The drugmakers said the European Union approval covers Lynparza as monotherapy for the maintenance treatment of adults with germline BRCA1/2 mutations who have metastatic adenocarcinoma of the pancreas and haven't progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.

AstraZeneca and Merck in 2017 formed a collaboration to co-develop and co-commercialize Lynparza for multiple cancer types.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

July 08, 2020 07:44 ET (11:44 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.